Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.32 |
| ▸ | KDM2B | Q8NHM5 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1962915 | 1.00 | HTR6 (0.36) | HTR6TDP1CTSCKDM2BALDH1A1 | |
| SCHEMBL2801307 | 1.00 | HTR6 (0.36) | HTR6TDP1CTSCKDM2BALDH1A1 | |
| SCHEMBL3337642 | 1.00 | HTR6 (0.36) | HTR6TDP1CTSCKDM2BALDH1A1 | |
| SCHEMBL9992744 | 1.00 | HTR6 (0.36) | HTR6TDP1CTSCKDM2BALDH1A1 | |
| SCHEMBL336904 | 1.00 | HTR6 (0.36) | HTR6TDP1CTSCKDM2BALDH1A1 | |
| SCHEMBL337871 | 0.95 | HTR6 (0.43) | HTR6TDP1DPP4 | |
| SCHEMBL24106650 | 0.81 | HTR6 (0.36) | HTR6CTSC | |
| SCHEMBL25270380 | 0.81 | HTR6 (0.36) | HTR6CTSC | |
| SCHEMBL24179707 | 0.81 | HTR6 (0.36) | HTR6CTSCALDH1A1DPP4 | |
| SCHEMBL8239226 | 0.81 | HTR6 (0.36) | HTR6CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10377772-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN S.A. (FR) | 2019-08-13 | — | — | US | disclosed |
| EP-3194405-B1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN SA (FR) | 2018-12-26 | — | — | EP | disclosed |
| US-20170240565-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2017-08-24 | — | — | US | disclosed |
| US-8097618-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2012-01-17 | — | — | US | disclosed |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2336136-A1 | Pyridine derivatives and their use in the treatment of psychotic disorders | GlaxoSmithKline LLC (US) | 2011-06-22 | — | — | EP | disclosed |
| US-7919491-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | GLAXOSMITHKLINE LLC (US) | 2010-06-17 | — | — | US | disclosed |
| US-7683056-B2 | Pyridine derivatives and their use in the treatment of psychotic disorders | GLAXOSMITHKLINE LLC (US) | 2010-03-23 | — | — | US | disclosed |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | KaNDy Therapeutics Limited (GB) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10377772-B2 | Macrocyclic LRRK2 kinase inhibitors | LRRK2, PINK1, PARK7 | HTR6 2608/4885TDP1 997/4885CTSC 1152/4885 |
| US-20110190276-A1 | Pyridine Derivatives And Their Use In The Treatment Of Psychotic Disorders | NDUFB7, NDUFB6, GABRE | HTR6 159/4885TDP1 2136/4885CTSC 4621/4885 |
| US-20170240565-A1 | MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, PINK1, PARK7 | HTR6 2608/4885TDP1 997/4885CTSC 1152/4885 |
| US-20080269208-A1 | Pyridine Derivatives and Their Use in the Treatment of Psychotic Disorders | SLC6A3, NDUFS5, NDUFB6 | HTR6 182/4885TDP1 2095/4885CTSC 3727/4885 |
| US-20100152175-A1 | Pyridine Derivatives and Their Use in The Treatment of Psychotic Disorders | CHRNA7, NR3C2, CHRNA6 | HTR6 100/4885TDP1 4277/4885CTSC 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.